Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T11:39:39.498Z Has data issue: false hasContentIssue false

Chemsex drugs: More than ghb, mephedrone and methamphetamine?

Published online by Cambridge University Press:  13 August 2021

J. Curto Ramos*
Affiliation:
Mental Health Service, University Hospital La Paz, MADRID, Spain
H. Dolengevich
Affiliation:
Hospital Del Henares, Mental Health Unit, Madrid, Spain
M.A. Morillas Romerosa
Affiliation:
La Paz Hospital, Mental Health Unit, Madrid, Spain
E. Mateos Pascual
Affiliation:
Hospital Juan Ramón Jiménez, Mental Health Unit, huelva, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The intentional use of drugs before or during sexual intercourse (chemsex), due to its impact on mental health, is a phenomenon of high importance in men who have sex with men. The main drugs usually described in chemsex related research are methamphetamine, mephedrone and GHB/GBL.

Objectives

We present a narrative review of the evidence about the mechanisms of action of different drugs used in chemsex context.

Methods

Narrative Review.

Results

Different drugs have been associated with chemsex use: stimulants such as cocaine, stimulants with empathogenic properties such as mephedrone, methamphetamine, MDMA; stimulants with a psychedelic effect such as 2C-B; depressants such as GHB/GBL and ethyl chloride; and dissociative hallucinogens such as ketamine.

Conclusions

Classical chemsex research includes only mephedrone, metanphetamine and GHB as “chemsex drugs”. Recently, different drugs have been described associated with chemsex practice. Clinicians may encounter polydrug chemsex users and the different mecanisms of action, mental health problems related to every drug and polydrug use must be takek into account.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.